Compare SJM & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SJM | QGEN |
|---|---|---|
| Founded | 1897 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 10.2B |
| IPO Year | N/A | 1996 |
| Metric | SJM | QGEN |
|---|---|---|
| Price | $101.84 | $44.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $116.42 | $49.74 |
| AVG Volume (30 Days) | ★ 1.8M | 1.2M |
| Earning Date | 11-25-2025 | 02-04-2026 |
| Dividend Yield | ★ 4.33% | 3.34% |
| EPS Growth | N/A | ★ 331.20 |
| EPS | N/A | ★ 1.84 |
| Revenue | ★ $8,773,200,000.00 | $2,070,781,000.00 |
| Revenue This Year | $4.88 | $7.12 |
| Revenue Next Year | $2.23 | $6.13 |
| P/E Ratio | ★ N/A | $24.59 |
| Revenue Growth | N/A | ★ 5.32 |
| 52 Week Low | $93.30 | $37.63 |
| 52 Week High | $121.48 | $51.88 |
| Indicator | SJM | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 47.45 | 40.20 |
| Support Level | $98.64 | $44.82 |
| Resistance Level | $101.41 | $47.48 |
| Average True Range (ATR) | 1.96 | 0.60 |
| MACD | 0.03 | -0.20 |
| Stochastic Oscillator | 57.85 | 4.26 |
J.M. Smucker is a packaged food company that primarily sells through the US retail channel (73% of fiscal 2025 revenue came through its retail pet foods, coffee, and frozen handheld/spreads segments), with the remaining share consisting of sweet baked snacks (through the Hostess acquisition) and international (primarily Canada). Retail coffee is its largest category (32% of sales) with brands Folgers and Dunkin'. Pet foods (19% of sales) holds leading brands like Milk-Bone and Meow Mix. Of its remaining, approximately 22% comes from frozen handhelds and spreads, through brands Jif, Smucker's, and Uncrustables. The company acquired Hostess Brands in fiscal 2024 to boost its snack and convenience store presence.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).